Literature DB >> 7690232

Haloperidol increases prolactin release and cyclic AMP formation in vitro: inverse agonism at dopamine D2 receptors?

C L Nilsson1, E Eriksson.   

Abstract

Haloperidol (30 nM, 3 microM) was found to increase prolactin release from GH4C 1 cells transfected with the D2 receptor cDNA (GH4ZR 7) and from wild-type (untransfected) GH 3 cells, but not from wild-type GH4C 1 cells. In addition, haloperidol (3 microM) stimulated cAMP formation in GH 3 cells. It is suggested that haloperidol may act as an inverse agonist rather than as a neutral antagonist at dopaminergic D2 receptors.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 7690232     DOI： 10.1007/bf01244880

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  23 in total

Review 1.  Reverse intrinsic activity of antagonists on G protein-coupled receptors.

Authors:  W Schütz; M Freissmuth
Journal:  Trends Pharmacol Sci       Date:  1992-10       Impact factor: 14.819

2.  Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand.

Authors:  T Costa; Y Ogino; P J Munson; H O Onaran; D Rodbard
Journal:  Mol Pharmacol       Date:  1992-03       Impact factor: 4.436

3.  The dopamine D2 receptor is expressed in GH3 cells.

Authors:  J M Johnston; D F Wood; E A Bolaji; D G Johnston
Journal:  J Mol Endocrinol       Date:  1991-10       Impact factor: 5.098

4.  Adenylyl cyclase from a prolactin producing tumor cell: the effect of phenothiazines.

Authors:  Y C Clement-Cormier; J J Heindel; G A Robison
Journal:  Life Sci       Date:  1977-11-01       Impact factor: 5.037

5.  Inhibition of calcium-dependent regulator-stimulated phosphodiesterase activity by neuroleptic drugs is unrelated to their clinical efficacy.

Authors:  J A Norman; A H Drummond; P Moser
Journal:  Mol Pharmacol       Date:  1979-11       Impact factor: 4.436

6.  Phenothiazines and haloperidol block Ca-activated K channels in rat forebrain synaptosomes.

Authors:  C G Benishin; B K Krueger; M P Blaustein
Journal:  Mol Pharmacol       Date:  1988-02       Impact factor: 4.436

7.  Modulation of dopamine receptors by cations in 7315a, MtTW15 and estradiol-induced pituitary tumors.

Authors:  K Coenen; T Di Paolo
Journal:  Biochem Pharmacol       Date:  1990-09-15       Impact factor: 5.858

8.  Coupling of a cloned rat dopamine-D2 receptor to inhibition of adenylyl cyclase and prolactin secretion.

Authors:  P R Albert; K A Neve; J R Bunzow; O Civelli
Journal:  J Biol Chem       Date:  1990-02-05       Impact factor: 5.157

9.  Sigma opiates and certain antipsychotic drugs mutually inhibit (+)-[3H] SKF 10,047 and [3H]haloperidol binding in guinea pig brain membranes.

Authors:  S W Tam; L Cook
Journal:  Proc Natl Acad Sci U S A       Date:  1984-09       Impact factor: 11.205

10.  Selective deficiency of guanine nucleotide-binding protein Go in two dopamine-resistant pituitary tumors.

Authors:  R Collu; C Bouvier; G Lagacé; C G Unson; G Milligan; P Goldsmith; A M Spiegel
Journal:  Endocrinology       Date:  1988-03       Impact factor: 4.736
View more
  3 in total

1.  Histamine H3-receptor-mediated [35S]GTP gamma[S] binding: evidence for constitutive activity of the recombinant and native rat and human H3 receptors.

Authors:  A Rouleau; X Ligneau; J Tardivel-Lacombe; S Morisset; F Gbahou; J-C Schwartz; J-M Arrang
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

Review 2.  Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism.

Authors:  Georges Vauquelin; Sophie Bostoen; Patrick Vanderheyden; Philip Seeman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-02-14       Impact factor: 3.000

3.  Molecular cloning of an orphan G-protein-coupled receptor that constitutively activates adenylate cyclase.

Authors:  D Eggerickx; J F Denef; O Labbe; Y Hayashi; S Refetoff; G Vassart; M Parmentier; F Libert
Journal:  Biochem J       Date:  1995-08-01       Impact factor: 3.857
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.